Within the investing sport, it’s not solely about what you purchase; it’s about while you purchase it. Probably the most frequent items of recommendation thrown across the Road, “purchase low” is touted as a tried-and-true tactic.Certain, the technique appears easy. Inventory costs naturally fluctuate on the premise of a number of components like earnings outcomes and the macro setting, amongst others, with buyers making an attempt to time the market and decide when shares have hit a backside. In apply, nonetheless, executing on this technique isn’t any simple job.On prime of this, given the volatility that has dominated the markets over the previous couple of weeks, how are buyers presupposed to gauge when a reputation is flirting with a backside? That’s the place the Wall Road professionals are available.These knowledgeable inventory pickers have recognized three compelling tickers whose present share costs land near their 52-week lows. Noting that every is about to take again off on an upward trajectory, the analysts see a pretty entry level. Utilizing TipRanks’ database, we discovered that the analyst consensus has rated all three a Robust Purchase, with main upside potential additionally on faucet.Progenity (PROG)Providing clear and actionable genetic outcomes, Progenity makes a speciality of offering testing companies. The corporate began buying and selling on Nasdaq in June and noticed its shares tumbling 44% since then. With shares altering fingers for $8.11, a number of members of the Road suggest pulling the set off earlier than it heats up.Piper Sandler analyst Steven Mah factors out that even in opposition to the backdrop of COVID-19, PROG managed to ship with its Q2 2020 efficiency. “We’re inspired by the restoration in late Q2 2020 with 75,000 accessioned assessments (~79,000 in Q1 2020), pushed by noninvasive prenatal testing (NIPT) and provider screening,” the analyst famous. Expounding on this, Mah said, “Progenity didn’t present steering, however June take a look at volumes of ~28,000 have been sturdy (Q1 2020 month-to-month common was ~26,000) which we imagine showcases the sturdiness of its reproductive assessments and the success that Progenity has in co-marketing and attaching provider screening to the extra important NIPT. Of be aware, regardless of the pandemic disruptions, Progenity was capable of preserve its main pre-COVID take a look at turnaround instances.”Moreover, well being insurer Aetna is briefly extending protection of average-risk NIPT till year-end on account of the pandemic, with the American School of Obstetricians and Gynecologists (ACOG) additionally anticipated to endorse average-risk sooner or later given its medical utility, in Mah’s opinion.Reflecting one other optimistic, the fourth era NIPT (single-molecule counting assay) take a look at was capable of measure fetal fraction, a key milestone in keeping with Mah, and can proceed to be developed into 2021. Because the expertise might doubtlessly be utilized to DNA, RNA, epigenetic markers and proteins for extra medical functions akin to oncology, the analyst is trying ahead to the completion of the preeclampsia verification in This fall 2020 and a attainable 2H21 launch. “We imagine preeclampsia (~2.Three billion serviceable market) is a significant differentiator for Progenity, permitting them to cross-sell throughout the full-continuum of reproductive testing,” the analyst added.If that wasn’t sufficient, PROG signed its first GI Precision Medication partnership settlement with a top-20 Pharma firm in August. The Oral Biotherapeutic Supply System (OBDS), an ingestible drug and gadget mixture designed to exactly ship biologics systemically by means of a needle-free liquid jet injection into the submucosal tissues of the small gut, is about to be utilized as a part of the collaboration. Mah commented, “We imagine Progenity can signal extra Pharma offers and sit up for the newsflow popping out on this entrance.”To sum all of it up, Mah stated, “We imagine Progenity shares are undervalued given the sturdy restoration within the core testing enterprise and a number of upcoming development catalysts.”To this finish, Mah charges PROG an Chubby (i.e. Purchase) together with a $17 worth goal. Ought to his thesis play out, a twelve-month achieve of 105% might doubtlessly be within the playing cards. (To look at Mah’s monitor document, click on right here)Are different analysts in settlement? They’re. Solely Purchase rankings, 4, in actual fact, have been issued within the final three months. Subsequently, the message is evident: PROG is a Robust Purchase. Given the $13.33 common worth goal, shares might climb 60% increased within the subsequent yr. (See PROG inventory evaluation on TipRanks)Tactile Methods Expertise (TCMD)Creating at-home remedy gadgets, Tactile Methods Expertise desires to supply new remedies for lymphedema, which happens when the lymphatic system is impaired, disrupting regular transport of fluid inside the physique, and persistent venous insufficiency. Down 52% year-to-date, its $32.67 share worth lands near its $29.47 52-week low. Thus, with enterprise tendencies enhancing, the Road is pounding the desk.Writing for Canaccord, analyst Cecilia Furlong acknowledges that the pandemic has hampered the corporate, with COVID-19 weighing on each volumes and gross sales. Within the second half of March, volumes have been down 50% in comparison with the primary half of the month, and TCMD’s affected person volumes in April and Could remained challenged. That being stated, tendencies began to enhance on the finish of Could.“Going ahead, given the overwhelming majority of TCMD’s clinician clients apply in outpatient or office-based settings, we stay optimistic on TCMD’s capacity to exhibit higher insulation in opposition to COVID impacts and sure expertise a better bounce-back relative to total med-tech quantity tendencies, with TCMD additional benefitting from its increasing utilizing of expertise to remotely have interaction with clinicians and help sufferers,” Furlong defined.The analyst added, “Moreover, current tendencies amongst some suppliers to prescribe Flexitouch (a sophisticated intermittent pneumatic compression gadget to self-manage lymphedema and nonhealing venous leg ulcers) earlier alongside the remedy course of, as a method to scale back in-person contact, might present upside close to time period, in addition to doubtlessly transition to a longer-term tailwind.”On prime of this, Furlong can also be optimistic about new CEO Dan Reuvers and the reprioritization of the corporate’s funding and market improvement efforts. TCMD will shift focus away from its acquired Airwear product line, with it redirecting investments towards its Flexitouch and Entre (a pneumatic compression gadget used to help within the residence administration of persistent swelling and venous ulcers related to lymphedema and persistent venous insufficiency) merchandise.“Given vital under-penetration within the lymphedema/phlebolymphedema market focused by Flexitouch alongside the massive affected person inhabitants with restricted therapy choices at this time focused by the agency’s Head & Neck platform, we view the mixture of training and medical knowledge as key to additional growing and penetrating these markets… Going ahead, we count on administration to proceed to compile a broad base of medical knowledge to help reimbursement and drive broad adoption,” Furlong commented.All of this prompted Furlong to maintain a Purchase score and $62 worth goal on the inventory. This goal conveys her confidence in TCMD’s capacity to soar 90% within the subsequent yr. (To look at Furlong’s monitor document, click on right here)Usually, different analysts are on the identical web page. With Three Purchase rankings and 1 Maintain, the phrase on the Road is that TCMD is a Robust Purchase. The $62.33 common worth goal brings the upside potential to 91%. (See TCMD inventory evaluation on TipRanks)uniQure N.V. (QURE)Final however not least we’ve uniQure, which delivers healing gene therapies that might doubtlessly rework the lives of sufferers. Though shares have fallen 44% year-to-date to $40, not a lot increased than its 52-week low of $36.20, a number of analysts nonetheless have excessive hopes.Representing SVB Leerink, 5-star analyst Joseph Schwartz acknowledges that shares struggled after information broke of its collaboration and licensing settlement with CSL Behring for AMT-061, QURE’s gene remedy for Hemophilia B, he argues the “shareholder base turnover is probably going now full as buyers and QURE shift focus to next-in-line AMT-130, its AAV5 gene remedy for Huntington’s Illness (HD).”Schwartz additional added, “With the M&A premium now out of the inventory, we see the QURE’s present stage as a pretty shopping for alternative for these buyers within the firm’s up and coming CNS gene therapies, inner manufacturing, and sturdy mental property and knowhow.”Trying extra carefully on the settlement with CSL Behring, QURE will probably be tasked with the completion of the pivotal Part Three HOPE-B trial in addition to the manufacturing course of validation and manufacturing provide of AMT-061.In keeping with administration, 26-week Issue IX (FIX) knowledge from all 54 sufferers enrolled within the trial stays on monitor, and topline knowledge from the pivotal trial continues to be slated to learn out by YE20. It must be talked about that in a Part 2b dose-confirmation examine, QURE reported 41% FIX exercise out to at least one yr. Moreover, Schwartz factors out that with HOPE-B progressing as deliberate, QURE has continued its manufacturing course of validation work forward of the anticipated BLA/MAA submissions within the U.S. and EU in 2021.On prime of this, as a part of the deal, QURE is eligible to obtain greater than $2 billion together with a $450 million upfront money fee, $1.6 billion in regulatory and business milestones and double-digit royalties ranging as much as the low-twenties share of internet product gross sales.“With a strengthened money place, QURE is nicely funded to quickly advance CNS property together with AMT-130 (AAV5 gene remedy for Huntington’s Illness (HD)) and AMT-150 (AAV gene remedy for Spinocerebellar Ataxia Sort 3/SCA3)…We proceed to imagine that as QURE’s CNS pipeline property mature, the corporate might as soon as once more be a pretty associate to bigger biopharma firms which have just lately acquired many publicly traded gene remedy platforms with substantial manufacturing capabilities,” Schwartz famous.All the things that QURE has going for it satisfied Schwartz to reiterate an Outperform (i.e. Purchase) score. Together with the decision, he hooked up a $67 worth goal, suggesting 68% upside potential from present ranges. (To look at Schwartz’s monitor document, click on right here)What does the remainder of the Road must say? 9 Buys and three Holds have been issued within the final three months, so the consensus score is a Robust Purchase. As well as, the $69.89 common worth goal signifies 75% upside potential. (See QURE inventory evaluation on TipRanks)To seek out good concepts for beaten-down shares buying and selling at enticing valuations, go to TipRanks’ Finest Shares to Purchase, a newly launched device that unites all of TipRanks’ fairness insights.Disclaimer: The opinions expressed on this article are solely these of the featured analysts. The content material is meant for use for informational functions solely. It is vitally necessary to do your personal evaluation earlier than making any funding.